Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
65.86 USD | +0.48% | +1.00% | -18.71% |
06:28pm | Ligand Pharmaceuticals Investing in Agenus to Fund Development of Oncology Drug Candidates | MT |
May. 02 | UBS Adjusts Price Target on Gilead Sciences to $70 From $75, Maintains Neutral Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.70% | 81.73B | |
+32.93% | 690B | |
+26.43% | 546B | |
-4.99% | 358B | |
+18.16% | 323B | |
+4.71% | 287B | |
+14.32% | 235B | |
+5.79% | 199B | |
-9.49% | 195B | |
+4.28% | 161B |
- Stock Market
- Equities
- GILD Stock
- News Gilead Sciences, Inc.
- Morgan Stanley Adjusts Price Target on Gilead Sciences to $78 From $80